<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:gild="http://gilead.com/20201023">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_03E_gild_gilead.com_20201023 -->
<!-- Field: Set; Name: xdx; ID: xdx_047_20201023_20201023 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0000882095 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
  <ix:hidden>
    <ix:nonNumeric contextRef="From2020-10-23to2020-10-23" name="dei:EntityCentralIndexKey">0000882095</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-10-23to2020-10-23" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    </ix:hidden>
  <ix:references>
    <link:schemaRef xlink:href="gild-20201023.xsd" xlink:type="simple" />
    </ix:references>
  <ix:resources>
    <xbrli:context id="From2020-10-23to2020-10-23">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-23</xbrli:startDate>
        <xbrli:endDate>2020-10-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    </ix:resources>
  </ix:header>
</div>


<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 14pt"><b>UNITED
STATES</b></span></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 14pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C. 20549</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-decoration: none; font-size: 14pt"><b>FORM
<span id="xdx_909_edei--DocumentType_c20201023__20201023_zkL0Fgvmvs8h"><ix:nonNumeric contextRef="From2020-10-23to2020-10-23" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Current Report</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section&#160;13 or 15(d)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of the Securities Exchange Act of 1934</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of Earliest Event
Reported):</b> <b><span id="xdx_90B_edei--DocumentPeriodEndDate_c20201023__20201023_zjWTqxBIklq6"><ix:nonNumeric contextRef="From2020-10-23to2020-10-23" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">October 23, 2020</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_90A_edei--EntityRegistrantName_c20201023__20201023_zSzWgcGSEoih"><b><ix:nonNumeric contextRef="From2020-10-23to2020-10-23" name="dei:EntityRegistrantName">Gilead Sciences, Inc.</ix:nonNumeric></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact Name of Registrant as Specified
in its Charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 34%; font-size: 10pt; text-align: center"><b><span id="xdx_905_edei--EntityIncorporationStateCountryCode_c20201023__20201023_zpJFJSOetv5e"><ix:nonNumeric contextRef="From2020-10-23to2020-10-23" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b><br />
    <b>(State or Other <br />
Jurisdiction<br />
    of Incorporation)</b></td>
    <td style="width: 32%; font-size: 10pt; text-align: center"><span id="xdx_904_edei--EntityFileNumber_c20201023__20201023_z7jkAzfo40v4"><b><ix:nonNumeric contextRef="From2020-10-23to2020-10-23" name="dei:EntityFileNumber">0-19731</ix:nonNumeric></b></span><br />
    <b>(Commission File Number)</b></td>
    <td style="white-space: nowrap; width: 34%">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_900_edei--EntityTaxIdentificationNumber_c20201023__20201023_zxAv7jPLsmS"><b><ix:nonNumeric contextRef="From2020-10-23to2020-10-23" name="dei:EntityTaxIdentificationNumber">94-3047598</ix:nonNumeric></b></span><br />
        <b>(I.R.S. Employer</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Identification No.)</b></p></td></tr>
<tr style="vertical-align: top">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><b><span id="xdx_90D_edei--EntityAddressAddressLine1_c20201023__20201023_zQLLj95W7Teb"><ix:nonNumeric contextRef="From2020-10-23to2020-10-23" name="dei:EntityAddressAddressLine1">333 Lakeside Drive</ix:nonNumeric></span><br />
 <span id="xdx_90D_edei--EntityAddressCityOrTown_c20201023__20201023_z2etWDY5E7U6"><ix:nonNumeric contextRef="From2020-10-23to2020-10-23" name="dei:EntityAddressCityOrTown">Foster City</ix:nonNumeric></span>, <span id="xdx_909_edei--EntityAddressStateOrProvince_c20201023__20201023_zQFageIUCSXb"><ix:nonNumeric contextRef="From2020-10-23to2020-10-23" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span></b></td>
    <td style="font-size: 10pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; white-space: nowrap"><b><span id="xdx_90E_edei--EntityAddressPostalZipCode_c20201023__20201023_zXEfwjuxpNnl"><ix:nonNumeric contextRef="From2020-10-23to2020-10-23" name="dei:EntityAddressPostalZipCode">94404</ix:nonNumeric></span></b></td></tr>
<tr style="vertical-align: top">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><b>(Address of Principal Executive Offices)</b></td>
    <td style="font-size: 10pt; text-align: center">&#160;</td>
    <td style="text-align: center; white-space: nowrap"><b>(Zip Code)</b></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Registrant&#8217;s telephone number,
including area code:&#160;(<span id="xdx_902_edei--CityAreaCode_c20201023__20201023_zcvS7KuUJ62h"><ix:nonNumeric contextRef="From2020-10-23to2020-10-23" name="dei:CityAreaCode">650</ix:nonNumeric></span>) <span id="xdx_90A_edei--LocalPhoneNumber_c20201023__20201023_zUI1XwNbD6R8"><ix:nonNumeric contextRef="From2020-10-23to2020-10-23" name="dei:LocalPhoneNumber">574-3000</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><b>Not Applicable</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Former Name or Former Address, if Changed
Since Last Report)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 97%; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in"><tr style="vertical-align: top">
<td style="width: 0.25in"><span style="font-family: Wingdings"><span id="xdx_90B_edei--WrittenCommunications_c20201023__20201023_zLUFSlknESe7"><ix:nonNumeric contextRef="From2020-10-23to2020-10-23" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</td></tr>                                                                                                                                                                                                                                                                                                       <tr style="vertical-align: top">
<td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
</table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 97%; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in"><tr style="vertical-align: top">
<td style="width: 0.25in"><span style="font-family: Wingdings"><span id="xdx_908_edei--SolicitingMaterial_c20201023__20201023_zCRVBiIFhZd7"><ix:nonNumeric contextRef="From2020-10-23to2020-10-23" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</td></tr>                                                                                                                                                                                                                                                                                                     <tr style="vertical-align: top">
<td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
</table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 97%; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in"><tr style="vertical-align: top">
<td style="width: 0.25in"><span style="font-family: Wingdings"><span id="xdx_907_edei--PreCommencementTenderOffer_c20201023__20201023_zc9qmsQOqVG1"><ix:nonNumeric contextRef="From2020-10-23to2020-10-23" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</td></tr>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     <tr style="vertical-align: top">
<td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td><span style="font-family: Wingdings"><span id="xdx_909_edei--PreCommencementIssuerTenderOffer_c20201023__20201023_zxv8ITiBvDfk"><ix:nonNumeric contextRef="From2020-10-23to2020-10-23" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Securities registered pursuant to Section 12(b)
of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; padding: 2pt 2pt 1pt; width: 33%; text-align: center; vertical-align: bottom"><b>Title of each class</b></td>
    <td style="width: 2%"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; padding: 2pt 2pt 1pt; width: 32%; text-align: center; vertical-align: bottom"><b>Trading Symbol(s)</b></td>
    <td style="width: 2%"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; padding: 2pt 2pt 1pt; width: 31%; text-align: center; vertical-align: bottom"><b>Name of each exchange on which&#160;registered</b></td></tr>
<tr style="vertical-align: top">
    <td style="padding: 2pt 2pt 1pt; text-align: center"><span id="xdx_909_edei--Security12bTitle_c20201023__20201023_zabe02ogW7za"><ix:nonNumeric contextRef="From2020-10-23to2020-10-23" name="dei:Security12bTitle">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="padding: 2pt 2pt 1pt; text-align: center"><span id="xdx_900_edei--TradingSymbol_c20201023__20201023_zK71M9TjatU6"><ix:nonNumeric contextRef="From2020-10-23to2020-10-23" name="dei:TradingSymbol">GILD</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="padding: 2pt 2pt 1pt; text-align: center"><span id="xdx_904_edei--SecurityExchangeName_c20201023__20201023_zhNAxBwtbmEb"><ix:nonNumeric contextRef="From2020-10-23to2020-10-23" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of
the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Emerging growth company&#160;&#160;<span style="font-family: Times New Roman, Times, Serif"><span style="font-family: Wingdings"><span id="xdx_908_edei--EntityEmergingGrowthCompany_c20201023__20201023_zEGUoUYAAute"><ix:nonNumeric contextRef="From2020-10-23to2020-10-23" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;<span style="font-family: Times New Roman, Times, Serif"><span style="font-family: Wingdings">&#168;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in"><b>Item 2.01.</b></td><td><b>Completion of Acquisition or Disposition of Assets.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As previously disclosed, on September&#160;13,
2020, Gilead Sciences,&#160;Inc., a Delaware corporation (&#8220;<span style="text-decoration: underline">Parent</span>&#8221; or &#8220;<span style="text-decoration: underline">Gilead</span>&#8221;), entered
into an Agreement and Plan of Merger (the &#8220;<span style="text-decoration: underline">Merger Agreement</span>&#8221;), among Parent,&#160;Immunomedics,&#160;Inc., a
Delaware corporation (&#8220;<span style="text-decoration: underline">Immunomedics</span>&#8221;), and Maui Merger Sub,&#160;Inc., a Delaware corporation and a wholly-owned
subsidiary of Parent (&#8220;<span style="text-decoration: underline">Purchaser</span>&#8221;). In accordance with the terms of the Merger Agreement, on October&#160;23,
2020, Gilead completed the acquisition of Immunomedics.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the Merger Agreement, and upon
the terms and subject to the conditions thereof, on September&#160;24, 2020, Purchaser commenced a tender offer (the &#8220;<span style="text-decoration: underline">Offer</span>&#8221;),
to purchase all of the issued and outstanding shares (the &#8220;<span style="text-decoration: underline">Shares</span>&#8221;) of common stock, par value $0.01 per share,
of Immunomedics, other than any Shares held immediately prior to the effective time of the Merger by Immunomedics (or held in Immunomedics&#8217;
treasury) and any Shares held immediately prior to the effective time of the Merger by Parent, Purchaser or any other direct or
indirect wholly owned subsidiary of Parent, at a price of $88.00 per Share (the &#8220;<span style="text-decoration: underline">Offer Price</span>&#8221;), net to the seller
in cash, without interest and subject to any required withholding of taxes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">The
Offer expired at one minute after 11:59 p.m., Eastern Time, on October&#160;22, 2020. According to Computershare Trust
Company, N.A., the depositary for the Offer, 188,227,162 Shares were validly tendered and not withdrawn in the Offer,
representing approximately 81.38% of the outstanding Shares (not including 12,451,797 Shares delivered through Notices of
Guaranteed Delivery, representing approximately 5.38% of the Shares outstanding). The number of Shares tendered satisfied the
condition to the Offer that there be validly tendered and not validly withdrawn prior to the expiration of the Offer </span>a
number of Shares that, considered together with all other Shares (if any) beneficially owned by Parent and its affiliates,
represent one more Share than 50% of the total number of Shares outstanding at the expiration of the Offer (excluding Shares
tendered by notice of guaranteed delivery <span style="font-family: Times New Roman, Times, Serif; background-color: white">that
have not yet been &#8220;received&#8221; (as such term is defined in Section&#160;251(h)(6)(f)&#160;of the </span>General
Corporation Law of the State of Delaware (the &#8220;<span style="text-decoration: underline">DGCL</span>&#8221;)<span style="font-family: Times New Roman, Times, Serif; background-color: white">)</span>).
All conditions to the Offer having been satisfied or waived, Gilead and Purchaser accepted for payment all Shares validly
tendered and not validly withdrawn.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Following the consummation of the Offer,
the remaining conditions to the Merger set forth in the Merger Agreement were satisfied or waived, and on October&#160;23, 2020,
Purchaser merged with and into Immunomedics pursuant to Section&#160;251(h)&#160;of the DGCL, with Immunomedics being the surviving
corporation (the &#8220;<span style="text-decoration: underline">Merger</span>&#8221;). At the effective time of the Merger, each Share (other than (i)&#160;Shares held
by Immunomedics (or held in Immunomedics&#8217; treasury), (ii)&#160;Shares held by Parent, Purchaser, or any other direct or indirect
wholly owned subsidiary of Parent and (iii)&#160;Shares held by stockholders who have properly exercised and perfected their demands
for appraisal of such Shares in accordance with the DGCL and have neither withdrawn nor lost such rights prior to the effective
time of the Merger) converted into the right to receive an amount in cash equal to the Offer Price, without interest and subject
to any required withholding of taxes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">The
aggregate consideration paid by Gilead to acquire the Shares in the Offer and Merger was approximately $21 billion. Gilead obtained
the funds necessary to fund the acquisition through (i)&#160;proceeds from the borrowings under the Term Loan Facility Credit Agreement
dated October&#160;23, 2020 among Gilead, as borrower, each lender from time to time party thereto and Barclays Bank PLC, as
administrative agent, consisting of a $1 billion senior unsecured term loan facility, (ii)&#160;proceeds from the offering of </span>senior
unsecured notes, consisting of $500 million aggregate principal amount of floating rate notes due 2021, $500 million aggregate
principal amount of floating rate notes due 2023, $2 billion aggregate principal amount of 0.75% senior notes due 2023, $1 billion
aggregate principal amount of 1.65% senior notes due 2030 and $1 billion aggregate principal amount of 2.60% senior notes due 2040,
on the terms and conditions previously disclosed in the final prospectus supplement filed by Gilead with the Securities and Exchange
Commission pursuant to Rule&#160;424(b)(5)&#160;on September&#160;25, 2020 and (iii)&#160;cash on hand.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The foregoing description of the Merger
Agreement and the transactions contemplated thereby does not purport to be complete and is qualified in its entirety by reference
to the Merger Agreement, a copy of which was filed as <a href="https://www.sec.gov/Archives/edgar/data/882095/000095010320017822/dp136480_ex0201.htm" style="-sec-extract: exhibit">Exhibit&#160;2.1 to the Current Report on Form&#160;8-K filed by Gilead with the Securities and Exchange Commission on September&#160;14, 2020 and which is incorporated by reference herein</a>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in"><b>Item 8.01.</b></td><td><b>Other Events.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On October&#160;23, 2020, Gilead issued
a press release announcing the completion of the acquisition of Immunomedics, a copy of which is attached as Exhibit&#160;99.1
to this Current Report on Form&#160;8-K and incorporated by reference herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in"><b>Item 9.01.</b></td><td><b>Financial Statements and Exhibits.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 3%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">(a)</span></td>
    <td style="font-size: 10pt; width: 97%"><span style="font: 10pt Times New Roman, Times, Serif">Financial Statements of Business Acquired</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">The financial
statements of Immunomedics required by this item will be filed by amendment to this Current Report on Form&#160;8-K no later than
71 calendar days after the date this Current Report on Form&#160;8-K is required to be filed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 3%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">(b)</span></td>
    <td style="font-size: 10pt; width: 97%"><span style="font: 10pt Times New Roman, Times, Serif">Pro Forma Financial Information</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">The pro forma
financial information required by this item will be filed by amendment to this Current Report on Form&#160;8-K no later than 71
calendar days after the date this Current Report on Form&#160;8-K is required to be filed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 3%; text-align: left">(d)</td><td style="text-align: justify; width: 97%">Exhibits</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 10%">
        <p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Exhibit&#160;<br />
Number</b></p></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 88%">
        <p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Description</b></p></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/882095/000095010320017822/dp136480_ex0201.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">2.1</span>*</a></td>
    <td>&#160;</td>
    <td style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/882095/000095010320017822/dp136480_ex0201.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Agreement and Plan of Merger, dated September&#160;13, 2020, among Immunomedics,&#160;Inc., Gilead Sciences,&#160;Inc. and Maui Merger Sub,&#160;Inc. (incorporated by reference to Exhibit&#160;2.1 to the Current Report on Form&#160;8-K filed by Gilead with the Securities and Exchange Commission on September&#160;14, 2020).</span></a></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td>&#160;</td>
    <td style="font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt"><a href="tm2030810d13_ex99-1.htm"><span style="font: 10pt Times New Roman, Times, Serif">99.1</span></a></td>
    <td>&#160;</td>
    <td style="font-size: 10pt"><a href="tm2030810d13_ex99-1.htm"><span style="font: 10pt Times New Roman, Times, Serif">Press Release, dated October&#160;23, 2020.</span></a></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td>&#160;</td>
    <td style="font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">104</span></td>
    <td>&#160;</td>
    <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Cover Page&#160;Interactive Data File (embedded within the Inline XBRL document).</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0"></p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in">*</td><td>Schedules omitted pursuant to Item 601(a)(5)&#160;of Regulation S-K. Gilead Sciences,&#160;Inc. agrees to furnish supplementally
a copy of any omitted schedule to the SEC upon request.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="padding-right: 5.75pt; font-size: 10pt"></td>
    <td colspan="2" style="padding-right: 5.75pt; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">GILEAD SCIENCES,&#160;INC.</span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.75pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="padding-right: 5.75pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.75pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="padding-right: 5.75pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 50%; padding-right: 5.75pt; font-size: 10pt"></td>
    <td style="padding-bottom: 1pt; width: 4%; padding-right: 5.75pt; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; width: 46%; padding-right: 5.75pt; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">/s/ Brett A. Pletcher</span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.75pt; font-size: 10pt">&#160;</td>
    <td style="padding-right: 5.75pt; font-size: 10pt">&#160;</td>
    <td style="padding-right: 5.75pt; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Name:&#160;&#160;&#160;&#160;Brett A. Pletcher</span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.75pt; font-size: 10pt">&#160;</td>
    <td style="padding-right: 5.75pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></td>
    <td style="padding-right: 5.75pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Title:&#160;&#160;&#160;&#160;&#160;&#160;Executive Vice President, Corporate</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.7pt">Affairs and General Counsel</p></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: October&#160;23, 2020</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5LpqWKto3LSpiFSkivka7SrDNlk38O5K3NLaIy8KyzHwzQoRiQXNdIcNhWuSww7qplEMo8IyM5oTekS1XKfhb4EVbx8q49v2BGXkGPTPoyePJC631ri2WKchRP0760RjkMB0kMFmL4KtnZM66ROO0qkCZErZMDWt0il9dwk49yVD9aqv2yFaTSSHqyU5+QyyjGDZ0Vw/iq4U8z0QQthOIBdOt+dbcrKMaZhXWvst26H+DDzhySXg= -->
